Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Emerging Stocks Down Under 3 May 2022: Kazia Therapeutics (ASX:KZA)
Kazia Therapeutics: A biotech taking on brain cancer
Kazia Therapeutics is tackling brain cancer, which is one of the deadliest forms of cancer. It’s lead asset Paxalisib has passed a Phase 2 and is currently in a Phase 3 study along with additional Phase 1 studies against other indications. We like this company for its cash reserves, the strong IP protection of its assets along with the work it has done to prepare for the drug’s eventual commercialisation.
Click here to read the previous edition of Emerging Stocks Down Under published 26 April 2022